|
US6471956B1
(en)
|
1994-08-17 |
2002-10-29 |
The Rockefeller University |
Ob polypeptides, modified forms and compositions thereto
|
|
US6001968A
(en)
|
1994-08-17 |
1999-12-14 |
The Rockefeller University |
OB polypeptides, modified forms and compositions
|
|
US6429290B1
(en)
|
1994-08-17 |
2002-08-06 |
The Rockefeller University |
OB polypeptides, modified forms and derivatives
|
|
US6350730B1
(en)
|
1994-08-17 |
2002-02-26 |
The Rockefeller University |
OB polypeptides and modified forms as modulators of body weight
|
|
US7597886B2
(en)
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
|
US6936439B2
(en)
|
1995-11-22 |
2005-08-30 |
Amgen Inc. |
OB fusion protein compositions and methods
|
|
US20030040467A1
(en)
|
1998-06-15 |
2003-02-27 |
Mary Ann Pelleymounter |
Ig/ob fusions and uses thereof.
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6664227B1
(en)
*
|
1996-03-01 |
2003-12-16 |
Genetics Institute, Llc |
Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
|
|
EP0812913A3
(en)
*
|
1996-06-12 |
1999-08-04 |
Smithkline Beecham Corporation |
HR-1 receptor, a receptor of the cytokine receptors family
|
|
US5986059A
(en)
|
1996-06-14 |
1999-11-16 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6335426B1
(en)
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6028176A
(en)
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
US6287801B1
(en)
*
|
1996-07-22 |
2001-09-11 |
Smithkline Beecham Corporation |
Nucleic acids encoding the G-protein coupled receptor HNFDS78
|
|
EA004790B1
(ru)
*
|
1996-12-20 |
2004-08-26 |
Амген Инк. |
Композиции на основе слитого белка ов и способы их применения
|
|
US6100387A
(en)
*
|
1997-02-28 |
2000-08-08 |
Genetics Institute, Inc. |
Chimeric polypeptides containing chemokine domains
|
|
US6852508B1
(en)
|
1997-02-28 |
2005-02-08 |
Genetics Institute, Llc |
Chemokine with amino-terminal modifications
|
|
DK1037927T3
(da)
|
1997-12-08 |
2004-09-06 |
Emd Lexigen Res Ct Corp |
Heterodimere fusionsproteiner, der er nyttige til målrettet immunterapi og generel immunstimulering
|
|
US7198789B2
(en)
|
1998-03-17 |
2007-04-03 |
Genetics Institute, Llc |
Methods and compositions for modulating interleukin-21 receptor activity
|
|
US6057128A
(en)
|
1998-03-17 |
2000-05-02 |
Genetics Institute, Inc. |
MU-1, member of the cytokine receptor family
|
|
EP1093457B8
(en)
|
1998-03-19 |
2011-02-02 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
US20010021380A1
(en)
*
|
1999-04-19 |
2001-09-13 |
Pluenneke John D. |
Soluble tumor necrosis factor receptor treatment of medical disorders
|
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
|
PL202058B1
(pl)
|
1999-08-09 |
2009-05-29 |
Merck Patent Gmbh |
Wielofunkcyjne białko fuzyjne cytokin i przeciwciała
|
|
JP2003514552A
(ja)
|
1999-11-12 |
2003-04-22 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
改善された性質を有するエリトロポエチンの形態
|
|
DE60122286T2
(de)
|
2000-02-11 |
2007-08-02 |
Merck Patent Gmbh |
Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen
|
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
|
EP2431054A3
(en)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
KR20060088905A
(ko)
|
2000-06-16 |
2006-08-07 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
면역특이적으로 ＢＬｙＳ에 결합하는 항체
|
|
ES2288967T3
(es)
|
2000-06-29 |
2008-02-01 |
Merck Patent Gmbh |
Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
|
|
TWI327600B
(en)
|
2000-11-28 |
2010-07-21 |
Medimmune Llc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
EP1683865A3
(en)
|
2001-02-02 |
2006-10-25 |
Eli Lilly & Company |
Mammalian proteins and in particular CD200
|
|
US7094892B2
(en)
*
|
2001-02-22 |
2006-08-22 |
The Research Foundation Of State University Of New York |
Nucleic acids encoding opiate receptors
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
BR0207854A
(pt)
|
2001-03-07 |
2004-08-24 |
Merck Patent Gmbh |
Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido
|
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
|
DK1385864T3
(da)
|
2001-04-13 |
2010-08-16 |
Human Genome Sciences Inc |
Anti-VEGF-2-antistoffer
|
|
HUP0400284A3
(en)
|
2001-05-03 |
2012-09-28 |
Merck Patent Gmbh |
Recombinant tumor specific antibody and use thereof
|
|
US7064189B2
(en)
|
2001-05-25 |
2006-06-20 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to trail receptors
|
|
US6867189B2
(en)
|
2001-07-26 |
2005-03-15 |
Genset S.A. |
Use of adipsin/complement factor D in the treatment of metabolic related disorders
|
|
PL206975B1
(pl)
|
2001-12-04 |
2010-10-29 |
Merck Patent Gmbh |
Immunocytokiny o modulowanej selektywności oraz ich zastosowanie
|
|
US7371383B2
(en)
|
2002-04-12 |
2008-05-13 |
Medimmune, Inc. |
Recombinant anti-interleukin-9 antibodies
|
|
AU2003276832A1
(en)
|
2002-05-10 |
2004-02-25 |
Medimmune, Llc |
EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
|
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
|
ES2381617T5
(es)
|
2002-08-14 |
2016-02-24 |
Macrogenics, Inc. |
Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
|
|
RU2366664C2
(ru)
|
2002-12-17 |
2009-09-10 |
Мерк Патент Гмбх |
Гуманизированное антитело (н14.18) на основании антитела 14.18 мыши, связывающееся с gd2, и его слияние с il-2
|
|
EP1594525A1
(en)
*
|
2003-01-18 |
2005-11-16 |
Children's Hospital Medical Center |
Regulation of allergen induced gene
|
|
AU2004206250B8
(en)
|
2003-01-21 |
2009-09-17 |
Bristol-Myers Squibb Company |
Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
|
|
EP1444989A1
(en)
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
|
CA2516455C
(en)
|
2003-02-20 |
2012-05-01 |
Seattle Genetics, Inc. |
Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
|
|
CN102040662A
(zh)
|
2003-03-14 |
2011-05-04 |
惠氏有限责任公司 |
抗人il-21受体的抗体及其应用
|
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
|
US20070253966A1
(en)
*
|
2003-06-12 |
2007-11-01 |
Eli Lilly And Company |
Fusion Proteins
|
|
ATE525395T1
(de)
*
|
2003-06-12 |
2011-10-15 |
Lilly Co Eli |
Fusions proteine von glp-1-analoga
|
|
WO2005042743A2
(en)
|
2003-08-18 |
2005-05-12 |
Medimmune, Inc. |
Humanization of antibodies
|
|
US7371381B2
(en)
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
|
BRPI0418286A
(pt)
|
2003-12-30 |
2007-05-02 |
Merck Patent Gmbh |
proteìnas de fusão de il-7
|
|
CA2551916C
(en)
|
2003-12-31 |
2014-04-29 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
|
EP1702069A2
(en)
|
2004-01-05 |
2006-09-20 |
EMD Lexigen Research Center Corp. |
Interleukin-12 targeted to oncofoetal fibronectin
|
|
WO2005097184A2
(en)
|
2004-03-26 |
2005-10-20 |
Human Genome Sciences, Inc. |
Antibodies against nogo receptor
|
|
DK1751184T3
(da)
|
2004-05-13 |
2009-11-23 |
Lilly Co Eli |
FGF-21 fusionsproteiner
|
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
|
US7501121B2
(en)
|
2004-06-17 |
2009-03-10 |
Wyeth |
IL-13 binding agents
|
|
CA2580921C
(en)
|
2004-09-21 |
2016-04-12 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
US7635754B2
(en)
*
|
2004-09-22 |
2009-12-22 |
Aerovance, Inc. |
Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
|
|
EP1809326A4
(en)
|
2004-10-27 |
2009-11-04 |
Medimmune Inc |
MODULATION OF ANTIBODY SPECIFICITY BY MEASURING ADAPTATION OF ITS AFFINITY TO AN APPARENT ANTIGEN
|
|
EP1824886B1
(en)
|
2004-11-17 |
2010-12-22 |
Amgen Inc. |
Fully human monoclonal antibodies to il-13
|
|
RU2437893C2
(ru)
|
2004-12-09 |
2011-12-27 |
Мерк Патент Гмбх |
Варианты il-7 со сниженной иммуногенностью
|
|
ATE435235T1
(de)
*
|
2004-12-22 |
2009-07-15 |
Lilly Co Eli |
Formulierungen glp-1-analoger fusionsproteine
|
|
WO2006102095A2
(en)
|
2005-03-18 |
2006-09-28 |
Medimmune, Inc. |
Framework-shuffling of antibodies
|
|
EP2511299A1
(en)
|
2005-04-19 |
2012-10-17 |
Seattle Genetics, Inc. |
Humanized anti-CD70 binding agents and uses thereof
|
|
ES2561628T3
(es)
|
2005-05-06 |
2016-02-29 |
Zymogenetics, Inc. |
Anticuerpos monoclonales IL-31 y métodos de uso
|
|
US20070110757A1
(en)
|
2005-06-23 |
2007-05-17 |
Ziping Wei |
Antibody formulations having optimized aggregation and fragmentation profiles
|
|
US7482124B2
(en)
|
2005-07-08 |
2009-01-27 |
Bristol-Myers Squibb Company |
Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
|
|
EA014900B1
(ru)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
|
|
US8592149B2
(en)
|
2006-04-27 |
2013-11-26 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
|
RU2009101783A
(ru)
|
2006-06-21 |
2010-07-27 |
Апогеникс Гмбх (De) |
Дифференциальная экспрессия цитокинов il-4 и/или il-10 в злокачественной опухоли человека
|
|
EP2505209A1
(en)
|
2006-06-26 |
2012-10-03 |
MacroGenics, Inc. |
Fcgamma-RIIB-specific antibodies and methods of the use thereof
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
EP2064243A2
(en)
|
2006-08-28 |
2009-06-03 |
Kyowa Hakko Kirin Co., Ltd. |
Antagonistic human light-specific human monoclonal antibodies
|
|
EP2594586B1
(en)
|
2006-09-01 |
2014-08-27 |
ZymoGenetics, Inc. |
IL-31 monoclonal antibodies and methods of use
|
|
EP2407548A1
(en)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Molecules with reduced half-lives, compositions and uses thereof
|
|
PT2099823E
(pt)
|
2006-12-01 |
2014-12-22 |
Seattle Genetics Inc |
Agentes de ligação ao alvo variantes e suas utilizações
|
|
CA2682170A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Antibodies with decreased deamidation profiles
|
|
JP5791895B2
(ja)
|
2007-05-04 |
2015-10-07 |
テクノファージ， インベスティガサン エ デセンボルビメント エム ビオテクノロジア，エスエー |
遺伝子操作されたウサギ抗体可変ドメイン及びその使用
|
|
CA2685222C
(en)
|
2007-05-14 |
2017-12-19 |
Medimmune, Llc |
Methods of reducing eosinophil levels
|
|
PL2796466T3
(pl)
|
2007-12-07 |
2018-04-30 |
Zymogenetics, Inc. |
Humanizowane cząsteczki przeciwciała swoiste dla il-31
|
|
BRPI0907046A2
(pt)
|
2008-01-18 |
2015-07-28 |
Medimmune Llc |
Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
|
|
EP2282773B2
(en)
|
2008-05-02 |
2025-03-05 |
Seagen Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
|
KR101030978B1
(ko)
*
|
2008-07-10 |
2011-04-28 |
(주) 에이프로젠 |
동물세포용 재조합 발현벡터
|
|
ES2643411T3
(es)
|
2008-08-05 |
2017-11-22 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a la proteína del complemento C5
|
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
EA201171259A1
(ru)
|
2009-04-22 |
2012-05-30 |
Мерк Патент Гмбх |
Антительные гибридные белки с модифицированными сайтами связывания fcrn
|
|
US20120134984A1
(en)
|
2009-06-01 |
2012-05-31 |
Olga Lubman |
Molecules with extended half-lives and uses thereof
|
|
AU2010270979B2
(en)
|
2009-06-22 |
2015-04-23 |
Medimmune, Llc |
Engineered Fc regions for site-specific conjugation
|
|
SMT201700293T1
(it)
|
2009-07-20 |
2017-07-18 |
Bristol Myers Squibb Co |
Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative
|
|
DK2464657T3
(en)
|
2009-08-10 |
2015-06-29 |
Morphosys Ag |
New screening strategies for the identification of antibodies or fragments thereof which bind an antigen with enzymatic activity
|
|
JP5883384B2
(ja)
|
2009-08-13 |
2016-03-15 |
ザ ジョンズ ホプキンス ユニバーシティー |
免疫機能を調節する方法
|
|
BR112012003064B8
(pt)
|
2009-08-13 |
2021-05-25 |
Crucell Holland Bv |
anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
|
|
WO2011035205A2
(en)
|
2009-09-18 |
2011-03-24 |
Calmune Corporation |
Antibodies against candida, collections thereof and methods of use
|
|
CA2798390A1
(en)
|
2010-05-06 |
2011-11-10 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
|
|
EP2566892B1
(en)
|
2010-05-06 |
2017-12-20 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
|
CN103140237A
(zh)
|
2010-07-09 |
2013-06-05 |
比奥根艾迪克依蒙菲利亚公司 |
因子ix多肽及其使用方法
|
|
US9139642B2
(en)
|
2010-07-09 |
2015-09-22 |
Crucell Holland B.V. |
Anti-human respiratory syncytial virus (RSV) antibodies and methods of use
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
PL2606070T3
(pl)
|
2010-08-20 |
2017-06-30 |
Novartis Ag |
Przeciwciała dla receptora epidermalnego czynnika wzrostu 3 (her3)
|
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
|
JP6327855B2
(ja)
|
2010-09-03 |
2018-05-23 |
アッヴィ・ステムセントルクス・エル・エル・シー |
新規モジュレータ及びその使用法
|
|
AU2011325833C1
(en)
|
2010-11-05 |
2017-07-13 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
|
CA2820885A1
(en)
|
2010-12-08 |
2012-09-07 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
US9540443B2
(en)
|
2011-01-26 |
2017-01-10 |
Kolltan Pharmaceuticals, Inc. |
Anti-kit antibodies
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
WO2012170742A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Treatment and prevention of cancer with hmgb1 antagonists
|
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
|
WO2012172495A1
(en)
|
2011-06-14 |
2012-12-20 |
Novartis Ag |
Compositions and methods for antibodies targeting tem8
|
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
|
US20150044208A1
(en)
|
2011-09-23 |
2015-02-12 |
Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa |
Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
|
|
WO2013067060A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
|
WO2013067055A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Methods of blocking cancer stem cell growth
|
|
US9221906B2
(en)
|
2011-11-01 |
2015-12-29 |
Bionomics Inc. |
Methods of inhibiting solid tumor growth by administering GPR49 antibodies
|
|
AU2012332590B2
(en)
|
2011-11-01 |
2016-10-20 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
|
AU2012332021B8
(en)
|
2011-11-04 |
2017-10-12 |
Zymeworks Bc Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP3252075A1
(en)
|
2011-11-04 |
2017-12-06 |
Novartis AG |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
|
US9453073B2
(en)
|
2011-12-02 |
2016-09-27 |
Eli Lilly And Company |
Anti-glucagon antibodies and uses thereof
|
|
SG11201402783YA
(en)
|
2011-12-05 |
2014-06-27 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
BR112014013568A2
(pt)
|
2011-12-05 |
2017-06-13 |
Novartis Ag |
anticorpos para o receptor do fator de crescimento epidermal 3 (her3) direcionados para o domínio ii do her3
|
|
SG10201703249PA
(en)
|
2011-12-21 |
2017-05-30 |
Novartis Ag |
Compositions and methods for antibodies targeting factor p
|
|
CA2859755C
(en)
|
2011-12-23 |
2021-04-20 |
Pfizer Inc. |
Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
|
|
PH12020500604A1
(en)
|
2012-02-24 |
2023-06-14 |
Abbvie Stemcentrx Llc |
Anti sez6 antibodies and methods of use
|
|
JP6089047B2
(ja)
|
2012-02-24 |
2017-03-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
Ｄｌｌ３モジュレーター及び使用方法
|
|
WO2013166594A1
(en)
|
2012-05-10 |
2013-11-14 |
Zymeworks Inc. |
Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
|
|
TWI596113B
(zh)
|
2012-07-25 |
2017-08-21 |
塞爾德克斯醫療公司 |
抗ｋｉｔ抗體及其用途
|
|
WO2014059028A1
(en)
|
2012-10-09 |
2014-04-17 |
Igenica, Inc. |
Anti-c16orf54 antibodies and methods of use thereof
|
|
WO2014084859A1
(en)
|
2012-11-30 |
2014-06-05 |
Novartis Ag |
Molecules and methods for modulating tmem16a activities
|
|
AU2013355414B2
(en)
|
2012-12-05 |
2017-02-02 |
Novartis Ag |
Compositions and methods for antibodies targeting EPO
|
|
KR20150095684A
(ko)
|
2012-12-18 |
2015-08-21 |
노파르티스 아게 |
히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
|
|
SMT201900339T1
(it)
|
2013-02-22 |
2019-07-11 |
Medimmune Ltd |
Coniugati anticorpo anti-dll3/pbd e loro usi
|
|
US20160067337A1
(en)
|
2013-03-14 |
2016-03-10 |
Bristol-Myers Squibb Company |
Combination of dr5 agonist and anti-pd-1 antagonist and methods of use
|
|
EP3611189A1
(en)
|
2013-03-14 |
2020-02-19 |
Novartis AG |
Antibodies against notch 3
|
|
CN103265637B
(zh)
*
|
2013-06-04 |
2015-10-21 |
江苏众红生物工程创药研究院有限公司 |
一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法
|
|
SG11201509982UA
(es)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
US9562101B2
(en)
|
2013-06-21 |
2017-02-07 |
Novartis Ag |
Lectin-like oxidized LDL receptor 1 antibodies and methods of use
|
|
AR096601A1
(es)
|
2013-06-21 |
2016-01-20 |
Novartis Ag |
Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
|
|
EP3041507B1
(en)
|
2013-08-26 |
2021-06-30 |
BioNTech Research and Development, Inc. |
Nucleic acids encoding human antibodies to sialyl-lewis a
|
|
JP2016538318A
(ja)
|
2013-08-28 |
2016-12-08 |
ステムセントリックス， インコーポレイテッド |
新規ｓｅｚ６モジュレーターおよび使用方法
|
|
EP3892294A1
(en)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Site-specific antibody conjugation methods and compositions
|
|
RU2016119491A
(ru)
|
2013-11-04 |
2017-12-11 |
Пфайзер Инк. |
Конъюгаты антитела к efna4 с лекарственным средством
|
|
SI3097122T1
(sl)
|
2014-01-24 |
2020-07-31 |
Ngm Biopharmaceuticals, Inc. |
Protitelesa, ki se vežejo v domeni beta klotho 2, in metode za njihovo uporabo
|
|
BR112016018891A2
(pt)
|
2014-02-21 |
2017-10-10 |
Abbvie Stemcentrx Llc |
anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
MX2016012873A
(es)
|
2014-04-04 |
2017-03-07 |
Bionomics Inc |
Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
|
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
|
CN106413750B
(zh)
|
2014-05-16 |
2022-04-29 |
免疫医疗有限责任公司 |
具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
|
|
AU2015271685B2
(en)
|
2014-06-04 |
2021-02-18 |
Biontech Research And Development, Inc. |
Human monoclonal antibodies to ganglioside GD2
|
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
|
US20170290876A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Compositions and methods for long acting proteins
|
|
DK3177642T3
(da)
|
2014-08-07 |
2022-02-21 |
Novartis Ag |
Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
|
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
|
CA2959786A1
(en)
|
2014-09-03 |
2016-03-10 |
Bioatla, Llc |
Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
WO2016094837A2
(en)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anti-c10orf54 antibodies and uses thereof
|
|
UY36449A
(es)
|
2014-12-19 |
2016-07-29 |
Novartis Ag |
Composiciones y métodos para anticuerpos dirigidos a bmp6
|
|
SG11201705988UA
(en)
|
2015-02-24 |
2017-08-30 |
Bioatla Llc |
Conditionally active biological proteins
|
|
DE112016001013T5
(de)
|
2015-03-03 |
2017-12-21 |
Kymab Limited |
Antikörper, verwendungen und verfahren
|
|
CA2982237A1
(en)
|
2015-06-05 |
2016-12-08 |
Novartis Ag |
Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
|
|
JOP20200312A1
(ar)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
الأجسام المضادة للعامل xi وطرق الاستخدام
|
|
WO2017021893A1
(en)
|
2015-08-03 |
2017-02-09 |
Novartis Ag |
Methods of treating fgf21-associated disorders
|
|
MX2018003038A
(es)
|
2015-09-09 |
2018-04-11 |
Novartis Ag |
Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
|
|
MY186352A
(en)
|
2015-09-09 |
2021-07-15 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
|
|
WO2017058859A1
(en)
|
2015-09-29 |
2017-04-06 |
Celgene Corporation |
Pd-1 binding proteins and methods of use thereof
|
|
JP7064769B2
(ja)
|
2015-11-02 |
2022-05-11 |
バイオアトラ、エルエルシー |
条件的活性型ポリペプチド
|
|
MA43372A
(fr)
|
2015-12-04 |
2018-10-10 |
Novartis Ag |
Compositions à greffe de cytokine-anticorps et procédés d'utilisation pour l'immunorégulation
|
|
AU2016370813A1
(en)
|
2015-12-18 |
2018-06-28 |
Novartis Ag |
Antibodies targeting CD32b and methods of use thereof
|
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
|
WO2017189724A1
(en)
|
2016-04-27 |
2017-11-02 |
Novartis Ag |
Antibodies against growth differentiation factor 15 and uses thereof
|
|
TW201802121A
(zh)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
抗因子XI/XIa抗體之逆轉結合劑及其用途
|
|
KR102492057B1
(ko)
|
2016-06-15 |
2023-01-26 |
노파르티스 아게 |
골 형태형성 단백질 6(ｂｍｐ6)의 억제제를 사용한 질병의 치료 방법
|
|
CN109641968B
(zh)
|
2016-07-06 |
2023-10-20 |
百时美施贵宝公司 |
Tim-4拮抗剂和pd-1拮抗剂的组合及其使用方法
|
|
CN109952317A
(zh)
|
2016-09-19 |
2019-06-28 |
细胞基因公司 |
使用pd-1结合蛋白治疗免疫病症的方法
|
|
JP2019534859A
(ja)
|
2016-09-19 |
2019-12-05 |
セルジーン コーポレイション |
Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
CN110325550B
(zh)
|
2016-12-23 |
2024-03-08 |
诺华股份有限公司 |
因子xi抗体和使用方法
|
|
JP7110199B2
(ja)
|
2016-12-23 |
2022-08-01 |
ノバルティス アーゲー |
抗第ＸＩ／ＸＩａ因子抗体による処置法
|
|
ES3035810T3
(en)
|
2017-02-08 |
2025-09-09 |
Novartis Ag |
Fgf21 mimetic antibodies and uses thereof
|
|
MX2019014023A
(es)
|
2017-05-24 |
2020-02-17 |
Novartis Ag |
Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
|
|
CN111107868A
(zh)
|
2017-05-24 |
2020-05-05 |
诺华股份有限公司 |
抗体细胞因子移植蛋白及使用方法
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
WO2018215937A1
(en)
|
2017-05-24 |
2018-11-29 |
Novartis Ag |
Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
|
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
|
US11707522B2
(en)
|
2017-10-13 |
2023-07-25 |
Boehringer Ingelheim International Gmbh |
Human antibodies to Tn antigen
|
|
US20210040205A1
(en)
|
2017-10-25 |
2021-02-11 |
Novartis Ag |
Antibodies targeting cd32b and methods of use thereof
|
|
CN112004558A
(zh)
|
2018-04-12 |
2020-11-27 |
米迪亚制药有限责任公司 |
Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
|
|
TWI869346B
(zh)
|
2018-05-30 |
2025-01-11 |
瑞士商諾華公司 |
Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法
|
|
US11492409B2
(en)
|
2018-06-01 |
2022-11-08 |
Novartis Ag |
Binding molecules against BCMA and uses thereof
|
|
MA53160A
(fr)
|
2018-07-20 |
2021-05-26 |
Pf Medicament |
Récepteur pour vista
|
|
AU2019349651B2
(en)
|
2018-09-27 |
2023-12-07 |
Celgene Corporation |
SIRP alpha binding proteins and methods of use thereof
|
|
UY38407A
(es)
|
2018-10-15 |
2020-05-29 |
Novartis Ag |
Anticuerpos estabilizadores de trem2
|
|
EP3947442A2
(en)
|
2019-03-28 |
2022-02-09 |
Danisco US Inc. |
Engineered antibodies
|
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
|
KR20250156861A
(ko)
|
2019-05-21 |
2025-11-03 |
노파르티스 아게 |
Cd19 결합 분자 및 이의 용도
|
|
TW202124446A
(zh)
|
2019-09-18 |
2021-07-01 |
瑞士商諾華公司 |
與ｅｎｔｐｄ２抗體之組合療法
|
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
|
TWI877278B
(zh)
|
2019-12-30 |
2025-03-21 |
美商思進公司 |
以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
|
|
WO2021202473A2
(en)
|
2020-03-30 |
2021-10-07 |
Danisco Us Inc |
Engineered antibodies
|
|
EP4143224A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Immunoglobulin variants
|
|
EP4143236A1
(en)
|
2020-05-01 |
2023-03-08 |
Novartis AG |
Engineered immunoglobulins
|
|
TW202212354A
(zh)
|
2020-08-03 |
2022-04-01 |
美商健生生物科技公司 |
用於病毒治療劑中之多向生物運輸的材料及方法
|
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
|
WO2022147463A2
(en)
|
2020-12-31 |
2022-07-07 |
Alamar Biosciences, Inc. |
Binder molecules with high affinity and/ or specificity and methods of making and use thereof
|
|
EP4362977A1
(en)
|
2021-06-29 |
2024-05-08 |
Seagen Inc. |
Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
|
|
UY40097A
(es)
|
2022-01-07 |
2023-07-14 |
Johnson & Johnson Entpr Innovation Inc |
Materiales y métodos de proteínas de unión a il-1b
|
|
CA3255838A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
MULTISPECIFIC ANTIBODIES TARGETTING IL-13 AND IL-18
|
|
JP2025525530A
(ja)
|
2022-07-15 |
2025-08-05 |
ヤンセン バイオテツク，インコーポレーテツド |
抗原結合可変領域の改善された生物工学による対合のための材料及び方法
|
|
EP4554619A1
(en)
|
2022-07-15 |
2025-05-21 |
Danisco US Inc. |
Methods for producing monoclonal antibodies
|
|
EP4612165A1
(en)
*
|
2022-11-02 |
2025-09-10 |
Synerkine Pharma B.V. |
Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
|
|
WO2024130158A1
(en)
|
2022-12-16 |
2024-06-20 |
Modernatx, Inc. |
Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
|
|
WO2025104604A1
(en)
|
2023-11-14 |
2025-05-22 |
Janssen Pharmaceuticals, Inc. |
Anti-respiratory syncytial virus antibodies and uses thereof
|